The announcement of promising Phase 1 data for VIR-5818 and VIR-5500 suggests potential future success in clinical trials, which could lead to increased investor confidence and a positive impact on Vir Biotechnology's stock price. The absence of dose-limiting cytokine release syndrome and the fact that the maximum tolerated dose has not yet been reached are positive indicators for the ongoing trials.